drugset / Trial / NCT05728944
Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ100 \& LNZ101 for the Treatment of Presbyopia
Timeline
- Start
- 2023-03-06
- Primary completion
- 2023-12-14
- Completion
- 2024-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aceclidine | Small molecule | — | — |
| Subject | Brimonidine | Small molecule | — | — |